Effectiveness of Benralizumab in Reducing Asthma and COPD Exacerbations in Patients with Severe Asthma and Concomitant COPD: Real-World Evidence from the ZEPHYR-5 Study.

Int J Chron Obstruct Pulmon Dis · 2026 · PMC12997770 · PMID 41859014

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

Consistent with the prior ZEPHYR-2 study, 22 a notable trend in respiratory medication use was also observed in the present study, with a decrease in the proportion of patients using most maintenance and short-acting rescue therapies following benralizumab initiation, with the exception of ICS/LAMA/LABA triple therapy.

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.